Celyad issues a White Paper about CAR T NKR-2 current knowledge and differences with classical CAR-T technologies

Celyad issues a White Paper about CAR T NKR-2 current knowledge and differences with classical CAR-T technologies

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells

Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA

Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA

Discover our news

Upcoming events

Apr 25-27, 2017

BioProcess International European Summit

May 15-16, 2017

Oxford Global Immuno-Oncology Congress

Jun 2-6, 2017

ASCO 2017

Discover all events

Press contacts

Stern Investor Relations (US)

Will O’Connor, Michael Schaffzin

+1 212 362 1200

Celyad

Marine Lhomel
Corporate Communications Manager

+32 (0)10 39 41 94

Consilium Strategic Communications (UK)

Chris Welsh, Chris Gardner

+44 20 3709 5700

NewCap (France)

Nicolas Merigeau, Pierre Laurent

+ 33(0)1 44 71 94 94

Comfi (Belgium)

Gunther De Backer, Sabine Leclercq

+32(0) 2 290 90 91